Overview
| 别名 | Eukaryotic translation initiation factor 2 subunit 2; Eukaryotic translation initiation factor 2 subunit beta; eIF2-beta |
| 基因名 | EIF2S2 |
| UniProt ID | P20042 |
| 反应种属 | Human |
| 应用 | WB |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG2a |
| 克隆号 | 3J6-Y2-O2 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 38 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | WB-1:1000 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Eukaryotic translation initiation factor 2 subunit beta (EIF2S2) is a fundamental component of the heterotrimeric eIF2 complex, which is essential for the initiation of eukaryotic protein synthesis. It participates in the formation of a ternary complex with GTP and initiator methionine tRNA, which then binds the 40S ribosomal subunit to create the 43S preinitiation complex. Following mRNA binding and GTP hydrolysis, the complex facilitates the assembly of the 80S ribosome. EIF2S2 also interacts with eIF2B to catalyze GDP-GTP exchange, recycling the eIF2 complex for subsequent rounds of initiation. Clinically, mutations in the EIF2S2 gene are linked to severe neurodevelopmental conditions, including MEHMO syndrome—characterized by intellectual disability, epilepsy, and microcephaly—and Leukoencephalopathy with Vanishing White Matter 5, highlighting its critical role in cellular proteostasis and neurological health. |
检测原理